<?xml version="1.0" encoding="utf8"?>
 <!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd"> <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">JNDC</journal-id>
      <journal-title-group>
        <journal-title>Journal of New Developments in Chemistry</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2377-2549</issn>
      <publisher>
        <publisher-name>Open Access Pub</publisher-name>
        <publisher-loc>United States</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">JNDC-21-4017</article-id>
      <article-id pub-id-type="doi">10.14302/issn.2377-2549.jndc-21-4017</article-id>
      <article-categories>
        <subj-group>
          <subject>research-article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Synthesis of 2-Chloro-2′-Deoxyadenosine (Cladribine) and New Purine Modified Analogues</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Grigorii</surname>
            <given-names>Sivets</given-names>
          </name>
          <xref ref-type="aff" rid="idm1842344860">1</xref>
          <xref ref-type="aff" rid="idm1842350044">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aleksey</surname>
            <given-names>Sivets</given-names>
          </name>
          <xref ref-type="aff" rid="idm1842344860">1</xref>
        </contrib>
      </contrib-group>
      <aff id="idm1842344860">
        <label>1</label>
        <addr-line>Institute of Bioorganic Chemistry, National Academy of Sciences, 220141 Minsk, Acad.</addr-line>
      </aff>
      <aff id="idm1842350044">
        <label>*</label>
        <addr-line>Corresponding author</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Jie</surname>
            <given-names>Xu</given-names>
          </name>
          <xref ref-type="aff" rid="idm1842467220">1</xref>
        </contrib>
      </contrib-group>
      <aff id="idm1842467220">
        <label>1</label>
        <addr-line>Wuhan Textile University.</addr-line>
      </aff>
      <author-notes>
        <corresp>
    
    Grigorii Sivets, <addr-line>National Academy of Sciences, Kuprevicha 5/2 , Belarus</addr-line><email>gsivets@mail.ru</email></corresp>
        <fn fn-type="conflict" id="idm1850719684">
          <p>The authors have declared that no competing interests exist.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub" iso-8601-date="2021-11-30">
        <day>30</day>
        <month>11</month>
        <year>2021</year>
      </pub-date>
      <volume>3</volume>
      <issue>4</issue>
      <fpage>1</fpage>
      <lpage>10</lpage>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>11</month>
          <year>2021</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>11</month>
          <year>2021</year>
        </date>
        <date date-type="online">
          <day>30</day>
          <month>11</month>
          <year>2021</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© </copyright-statement>
        <copyright-year>2021</copyright-year>
        <copyright-holder>Grigorii Sivets, et al.</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://openaccesspub.org/jndc/article/1732">This article is available from http://openaccesspub.org/jndc/article/1732</self-uri>
      <abstract>
        <p>Theefficient two-step synthesis of                     2-chloro-2′-deoxyadenosine (cladribine) via the anion glycosylation of purine potassium salt with the glycosyl chloride in binary solvent mixtures is described. A new method for preparation of                  diprotected 2-chloro-6-fluoropurine 2′-deoxy-β-           D-riboside was developed by treatment of the 2,6-dichloropurine precursor with diethylaminosulfur trifluoride (DAST). Novel N6-alkylated cladribine analogue was synthesized by amination of acylated 2,6-dihalogenopurine nucleosides. It was found that a mild hydrolysis reaction of acylated 2-chloro-6-fluoropurine 2′-deoxy-β-D-riboside gave rise to new purine hydroxylated nucleoside.</p>
      </abstract>
      <kwd-group>
        <kwd>Anticancer purine nucleoside</kwd>
        <kwd>glycosyl chloride</kwd>
        <kwd>stereoselective anion glycosylation</kwd>
        <kwd>fluorination reaction</kwd>
        <kwd>mechanism</kwd>
      </kwd-group>
      <counts>
        <fig-count count="4"/>
        <table-count count="1"/>
        <page-count count="10"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="idm1842213484" sec-type="intro">
      <title>Introduction</title>
      <p>Among a series of known antineoplastic agents belonging to the purine nucleosides, cladribine have found application as the clinical drug for the treatment of hematologic malignances. The cladribine (2-chloro-2′-deoxyadenosine), deaminase-resistant analogue of 2′-deoxyadenosine is used for                       monotherapy of patients with hairy cell leukemia <xref ref-type="bibr" rid="ridm1842115644">1</xref> and treatment of other lymphoid malignances. Its mechanism of significant cytotoxicity and metabolism was widely studied and it has been established that the active metabolite, 5′-triphosphate, inhibits DNA synthesis and ribonucleotide reductase activity <xref ref-type="bibr" rid="ridm1842184332">2</xref><xref ref-type="bibr" rid="ridm1842193044">3</xref>. Recently, cladribine has also been approved as the oral drug with a promising efficacy and safety                       profile <xref ref-type="bibr" rid="ridm1841972924">4</xref> for the treatment of relapsing multiple sclerosisin adults <xref ref-type="bibr" rid="ridm1841969684">5</xref><italic>.</italic></p>
      <p>The synthesis of cladribine has widely been              investigated in the framework of several approaches a) glycosylation reactions of purine derivatives with sugars <xref ref-type="bibr" rid="ridm1841957276">6</xref><xref ref-type="bibr" rid="ridm1841961668">7</xref><xref ref-type="bibr" rid="ridm1841950500">8</xref><xref ref-type="bibr" rid="ridm1841946612">9</xref>; b) C2′-deoxygenation of selectively protected              purine nucleoside derivative <xref ref-type="bibr" rid="ridm1841930676">10</xref>; c) enzymatic                    transglycosylation or glycosylation reactions <xref ref-type="bibr" rid="ridm1841925924">11</xref><xref ref-type="bibr" rid="ridm1841921676">12</xref><xref ref-type="bibr" rid="ridm1841919084">13</xref>. It should be noted, of the known synthetic approaches, the most studied method is derived from glycosylation                    reactions of purine nucleobase derivative with an                    activated carbohydrate. The sodium salts of halogenated purines give N9 and N7 glycosyl isomers under the             glycosylation and the stereoselectivity varies with                    heterocyclic bases and the reaction conditions <xref ref-type="bibr" rid="ridm1841921676">12</xref><xref ref-type="bibr" rid="ridm1841919084">13</xref>.This challenge was solved via highly stereoselective                   glycosylation of 6-substituted imidazol-1-yl-2-chloropurines with protected 1-chloro-2-deoxyribose in a mixture of solvents, using Robins’ purine salt method, and cladribine was prepared in three steps from the                          N6-modified purine <xref ref-type="bibr" rid="ridm1841901420">14</xref>. A practical and efficient process for the manufacture of cladribine was developed via the Vorbrüggen glycosylation of silylated base with 1-acetoxy 2-deoxyribofuranose derivative <xref ref-type="bibr" rid="ridm1841925924">11</xref>. N6<italic>-</italic>alkylated purine 2′-deoxyribonucleoside analogues display <italic>in vitro</italic>            anticancer and antiviral activities <xref ref-type="bibr" rid="ridm1841895372">15</xref><xref ref-type="bibr" rid="ridm1841908764">16</xref>. Because of our interest in extending preparation of biologically active nucleosides from sugars, herein we report study of                   efficient two-step synthetic route to 2-chloro-2′-deoxyadenosine via stereoselective anion glycosylation of purine base with the carbohydrate precursor using readily available reagents and development of simple synthetic approaches to its novel purine modified analogues. </p>
    </sec>
    <sec id="idm1842212332" sec-type="results">
      <title>Results and Discussion </title>
      <p>Synthesis of cladribine 3 was explored via                    selective glycosylation of the potassium salt of                            2,6-dichloropurine with available 1-α-chlorosugar 1 <xref ref-type="bibr" rid="ridm1841902428">17</xref> using various reaction conditions on the key step to                increase its regioselectivity (<xref ref-type="fig" rid="idm1850386012">Scheme 1</xref>, <xref ref-type="table" rid="idm1850385076">Table 1</xref>).                      Regioselective coupling of the potassium salt of                                           2,6-dichloropurine, generated in the presence of                      potassium<italic> tert</italic>-butoxide in 1,2-dimethoxyethane, with                  1-chloro-2-deoxy-3,5-di-O-p-toluoyl-α-D-<italic>erythro</italic>-pentofuranosyl chloride (1) at ambient temperature in a                   mixture of anhydrous acetonitrile and tetrahydrofuran resulted in formation of 3′,5′-di-O-toluoyl-2,6-dichloropurine-2′-deoxy-β-D-riboside (<bold>2</bold>) as predominant product. <sup>1</sup>H NMR data of the crude reaction mixture                indicate that glycosylation proceeds with full conversion of the starting 1-α-chlorosugar to a mixture of three                 nucleosides, giving acylated N9-β-2′-deoxy-β-D-riboside along with the undesired N9-α- and N7-β-isomeric                 nucleosides as by-products. A ratio of acylated N9-β/            N7-β-regioisomers made up 6.2:1 (<xref ref-type="table" rid="idm1850385076">Table 1</xref>, entry 1).                Protected N9-2′-deoxy-β-D-nucleoside <bold>2</bold> was prepared in 70% yield after column chromatography on silica gel. The anion glycosylation reaction of 2,6-dichloropurine salt in anhydrous tetrahydrofuran in the presence of 18 crown 6 resulted in the intermediate N9-β-nucleoside <bold>2</bold> in 61% yield after chromatographic separation, N9-β/                        N7-β-regioisomeric nucleosides being formed in a ratio of 5.2:1 (entry 2). The glycosylation reaction in THF, the            solvent with a lower polarity, and in the presence of crown ether as additive for improving solubility of the purine salt gave rise to decrease of the reaction time, yield of the protected N9-β-nucleoside and stereoselectivity compared to the reaction in a binary mixture of solvents (Scheme 1, conditions a<sub>1 </sub>and a<sub>2</sub>).Next,the glycosylation reaction of the potassium salt of 2,6-dichloropurine in a binary solvent mixture (acetonitrile and 3,4 dihydro-2H-pyran as component with lower polarity) gave the best regioselectivity (ratio of protected N9-β/              N7-β-/N9-α-nucleosides ‒ 10:1:1)(entry 3). The protected N9-β-nucleoside 2 was isolated in 67-70%yield after             column chromatography on silica gel using mixtures of petroleum ether and ethylacetate. The above results on the anion glycosylation of the 2,6-dichloropurine salt with the 1-α-chlorosugar under tested conditions provide                 evidence for regio- and stereoselectivity of the reaction depends on rational choice of solvents with different       solvation of the purine potassium salt and a minimal anomerization of the starting sugar. Fast anion                          glycosylation of the purine potassium salt with the                    1-α-chlorosugar in binary solvent mixtures improves the stereoselectivity of the heterogeneous reaction to give higher isolated yield of acylated N9-β-nucleoside than the sodium salt glycosylation in acetonitrile <xref ref-type="bibr" rid="ridm1841961668">7</xref>. Protected                 2′-deoxy-β-D-ribonucleoside of 2,6-dichloropurine 2 was then converted to cladribine 3 in NH<sub>3</sub>/MeOH/THF.                 Selectiveammonolysis of 2 occurring with the                       deprotection gave 2-chloro-2'-deoxyadenosine (3) in 82% yield after column chromatography. The improved                  approach to cladribine via coupling of the potassium salt of 2,6-dichloropurine with the 1-α-chlorosugar in a                mixture of solvents was accomplished using commercially available reagents. It should be noted that overall yields (50-56%) of the target nucleoside are comparable to those for efficient chemical approaches (42-63%) developed from 2-deoxy-D-ribofuranose derivatives <xref ref-type="bibr" rid="ridm1841957276">6</xref><xref ref-type="bibr" rid="ridm1841961668">7</xref><xref ref-type="bibr" rid="ridm1841946612">9</xref><xref ref-type="bibr" rid="ridm1841901420">14</xref> and 2-chloroadenosine <xref ref-type="bibr" rid="ridm1841930676">10</xref>, or the enzymatic method (59%) described from thymidine <xref ref-type="bibr" rid="ridm1841919084">13</xref>. However, inherent drawbacks of the studied method are the formation of N-9- and                       N-7-isomers on the glycosylation step, unlike the                    enzymatic methods <xref ref-type="bibr" rid="ridm1841925924">11</xref><xref ref-type="bibr" rid="ridm1841921676">12</xref><xref ref-type="bibr" rid="ridm1841919084">13</xref>, and the use of                              chromatography on two steps in comparison with the        cost-efficient and practical four-step procedure via the Vorbrüggen glycosylation of silylated 2-chloroadenine (overall 42%) <xref ref-type="bibr" rid="ridm1841957276">6</xref>. When this method is compared with the known synthetic routes derived from 2,6-dichloropurine and 2-deoxy-D-ribofuranose derivatives it is apparent that cladribine synthesis via the glycosylation of the potassium purine salt in a binary mixture of solvents and                     ammonolysis under mild reaction conditions (<xref ref-type="fig" rid="idm1850386012">Scheme 1</xref>) produced higher overall yield (56%) than the sodium salt method (42%) <xref ref-type="bibr" rid="ridm1841961668">7</xref>. Besides, the studied two-step approach is more accessible than the five-step method reported    earlier via the stereoselective glycosylation of                            2,6-dichloropurine with peracylated 2-deoxy-D-ribofuranose in the presence of gold-containing catalyst <xref ref-type="bibr" rid="ridm1841946612">9</xref> and less efficient than Robins’ purine salt method <xref ref-type="bibr" rid="ridm1841901420">14</xref>. </p>
      <fig id="idm1850386012">
        <label>Scheme 1.</label>
        <caption>
          <title> Syntheses of cladribine 3 from 1-α-chlorosugar 1 </title>
        </caption>
        <graphic xlink:href="images/image1.jpg" mime-subtype="jpg"/>
      </fig>
      <table-wrap id="idm1850385076">
        <label>Table 1.</label>
        <caption>
          <title> Reactions of potassium salt of 2,6-dichloropurine with the chlorosugar 1 under various conditions </title>
        </caption>
        <table rules="all" frame="box">
          <tbody>
            <tr>
              <td>Entry</td>
              <td>Solvent</td>
              <td>Conditions Ratio of heterobase: chlorosugar</td>
              <td>Time (min)</td>
              <td>Anomeric ratios              (N-9-β:N7-β)<sup>a </sup></td>
              <td>Yield (%)<sup>b</sup></td>
            </tr>
            <tr>
              <td>1</td>
              <td>MeCN/THF (1:1.2)</td>
              <td>1.1:1</td>
              <td>150 min</td>
              <td>6.2:1</td>
              <td>70</td>
            </tr>
            <tr>
              <td>2</td>
              <td>THF<sup>c</sup></td>
              <td>1.1:1</td>
              <td>120 min</td>
              <td>5.2:1</td>
              <td>61</td>
            </tr>
            <tr>
              <td>3</td>
              <td>MeCN/3,4-DHP(1:1.1)</td>
              <td>1.1:1</td>
              <td>150 min</td>
              <td> 10.0:1</td>
              <td>67-70</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="idm1842157212">
            <label/>
            <p><sup>a</sup>Determined by 1H NMR spectroscopy of the reaction mixture in CDCl<sub>3</sub></p>
          </fn>
          <fn id="idm1842156492">
            <label/>
            <p><sup>b</sup>Isolated yield of protected purine N9-β-2´-deoxynucleoside 2 by column chromatography.</p>
          </fn>
          <fn id="idm1842156348">
            <label/>
            <p><sup>c</sup>18 Crown 6 (0.1 eqiuv) was used as additive.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Synthesis of new N6-alkylated derivative of cladribine containing a branched alkyl substituent was investigated from 3′,5′-di-O-p-toluoyl-2′-deoxy-β-D-riboside of 2,6-dichloropurine 2. Several synthetic                   approaches to biologically active N6-substituted purine nucleosides were described earlier <xref ref-type="bibr" rid="ridm1841873748">18</xref> and the most               employed methods are based upon introduction of a           leaving group (halogen, aryl sulfonate, or                                        O-benzotriazolyl) at the C-6 position of nucleoside                   derivative followed by a selective nucleophilic S<sub>N</sub>Ar                displacement with the corresponding alkyl amines <xref ref-type="bibr" rid="ridm1841895372">15</xref>. Fluorination of O-protected 2,6-dichloropurine                              2′-deoxy-β-D-ribonucleoside 2 was performed with an excess of DAST in a mixture of CH<sub>2</sub>Cl<sub>2</sub>/pyridine under mild heating (<xref ref-type="fig" rid="idm1850292236">Scheme 2</xref>). </p>
      <fig id="idm1850292236">
        <label>Scheme 2.</label>
        <caption>
          <title> Synthesis of N6-alkylated cladribine derivative 6</title>
        </caption>
        <graphic xlink:href="images/image2.jpg" mime-subtype="jpg"/>
      </fig>
      <p>We have found for the first time that such                   treatment of protected 2,6-dichloropurine                                     2´-deoxyriboside by the nucleophilic fluorinating reagent gave rise to 2-chloro-6-fluoropurine derivative 4 in 58% yield after chromatography on silica gel. Syntheses of                   6-fluorinated purine nucleosides and heterocyclic bases have earlier been reported in several works <xref ref-type="bibr" rid="ridm1841872740">19</xref><xref ref-type="bibr" rid="ridm1841867772">20</xref><xref ref-type="bibr" rid="ridm1841862516">21</xref>.                Selective fluorination reaction of 2 likely to proceed by two pathways A and B via formation of activated                    intermediates 7, 8, and 9 followed by nucleophilic S<sub>N</sub>Ar              6-chlorine displacement with DAST in adducts 7 and 9 (<xref ref-type="fig" rid="idm1850292020">Scheme 3</xref>)<italic>. </italic>Based on a previous study of synthesis of                 6-fluorinated purines and the known method <xref ref-type="bibr" rid="ridm1841862516">21</xref>                    developed by Deng et al., we can conclude that pathway A via formation of intermediate salt 7 is a predominant.</p>
      <fig id="idm1850292020">
        <label>Scheme 3.</label>
        <caption>
          <title> Proposed mechanism for fluorination reaction of 2,6-dichloropurine                 nucleoside 2 with DAST</title>
        </caption>
        <graphic xlink:href="images/image3.jpg" mime-subtype="jpg"/>
      </fig>
      <p>Further, we investigated comparable amination of protected 2-chloro-6-fluoropurine (4) and 2,6-dichloropurine (2) 2′-deoxy-β-D-ribosides with                   isopropyl amine in similar reaction conditions. Reactions of 2,6-dihalogenated purine derivatives 2 and 4 using fourfold excess of diisopropylamine in                                           1,2-dimethoxyethane at room temperature resulted in               N6-alkylated purine analogue 5 in 81% and 89% yield, respectively, after chromatography on silica gel (<xref ref-type="fig" rid="idm1850292236">Scheme 2</xref>).<sup>1</sup>H NMR spectral data of N6-isopropyl purine derivative 5 synthesized from 2,6-dichloropurine and 2-chloro-6-fluoropurine derivatives were identical, that unequivocally confirms the assigned structure of new 2-chloro-6-fluoropurine nucleoside precursor 4. Noteworthy, a              selective amination of 4 proceeded in higher yield and shorter reaction time than the same transformation of                2,6-dichloropurine derivative 2. Thus, protected 2-chloro-6-fluoropurine 2′-deoxy-β-D-riboside can be utilized as valuable intermediate for preparation of different N6 or C6-substituted purine 2′-deoxyribonucleosides of            biological interest via S<sub>N</sub>Ar selective mild displacement of fluorine atom by various nucleophilic agents. Deprotection of O-acylated N6-isopropyl purine nucleoside 5 with                 ammonia in methanol afforded novel cladribine analogue 6 in 79% yield after column chromatography on silica gel. Then, hydrolysis reaction of 2-chloro-6-fluoropurine                  2′-deoxy-β-D-ribofuranoside 4 was studied under mild basic treatment with sodium hydrocarbonate in acetonitrile (<xref ref-type="fig" rid="idm1850263436">Scheme 4</xref>). New purine modified nucleoside 14 was prepared in 65% yield after chromatography on silica gel. A possible mechanism for formation of hydroxylated purine nucleoside 14 via S<sub>N</sub>Ar selective displacement of fluorine atom in 4 on the first step and subsequent                              transformations of intermediate 2-chloro-3′,5′-di-O-p-toluoyl-2′-deoxyinosine (10) in the heterobase under mild basic conditions is outlined in Scheme 4. Structures of  synthesized novel purine modified nucleosides were             confirmed by <sup>1</sup>H, <sup>13</sup>C, <sup>19</sup>F NMR and mass-spectroscopy. Signal of F-6 atom in 2-chloro-6-fluoropurine nucleoside 4                 displays as a singlet at - 65.59 ppm in <sup>19</sup>F NMR spectrum. Chemical shift of fluorine atom in 2-chloro-6-fluoropurine derivative 4 is in good accordance with <sup>19</sup>F NMR spectral data of tri-O-acetylated 2-chloro-6-fluoropurine                             β-ribonucleoside described earlier <xref ref-type="bibr" rid="ridm1841872740">19</xref>. The presence of hydroxy groups at 3.9-4.5 ppm and absence of signal for NH proton (8.1-10.0 ppm) in <sup>1</sup>H NMR spectrum and peak of <sup>M+Na</sup><sup>+</sup> in mass-spectrum support the assigned                    structure of hydroxylated purine nucleoside 14. </p>
      <fig id="idm1850263436">
        <label>Scheme 4.</label>
        <caption>
          <title> Synthesis of purine modified 2′-deoxynucleoside 14 from                      2-chloro-6-fluoropurine derivative 4 </title>
        </caption>
        <graphic xlink:href="images/image4.jpg" mime-subtype="jpg"/>
      </fig>
    </sec>
    <sec id="idm1842133700" sec-type="conclusions">
      <title>Conclusion</title>
      <p>In summary, the improved cladribine synthesis was achieved using the 2,6-dichloropurine potassium salt in the coupling reaction with available 1-α-chlorosugar and subsequent mild ammonolysis of the intermediate nucleoside. Solvent effects on stereoselectivity and                   regioselectivity of the glycosylation procedure were                  established. A new method to synthesize diprotected                   2-chloro-6-fluoropurine 2′-deoxy-β-D-ribofuranoside was developed for the first time from the 2,6-dichloropurine nucloside using nucleophilic fluorinating agent and a               plausible mechanism for formation of                                                2-chloro-6-fluoropurine derivative was proposed by                 selective nucleophilic S<sub>N</sub>Ar 6-chlorine displacement in the starting nucleoside with DAST. The efficient synthesis of N6-alkylated cladribine analogue was accomplished via a selective amination of 2-chloro-6-fluoropurine nucleoside derivative. New purine modified nucleoside derivative was prepared by hydrolysis reaction of acylated                            2-chloro-6-fluoropurine 2′-deoxy-β-D-ribofuranoside and a possible mechanism for its formation was considered. </p>
    </sec>
    <sec id="idm1842130964" sec-type="materials">
      <title>Materials and Methods</title>
      <p>Column chromatography was performed on silica gel 60 H (70-230 mesh; Merck, Darmstadt, Germany), and thin-layer chromatography (TLC) on Merck silica gel                aluminum 60 F<sub>254</sub> precoated plates. The anhydrous         solvents were distilled over CaH<sub>2</sub>, P<sub>2</sub>O<sub>5</sub> or magnesium   prior to the use. All commercially available reagents were used without further purification. <sup>1</sup>H, <sup>13</sup>C, and <sup>19</sup>F NMR spectra were recorded in CDCl<sub>3</sub>, CD<sub>3</sub>OD and DMSO-d<sub>6</sub> with a Bruker Avance-500-DRX spectrometer at 500.13, 126.76 and 470.59 MHz, respectively. <sup>1</sup>H and<sup>13</sup>C NMR chemical shifts (δ, ppm) are relative to internal chloroform peak (7.26 ppm for <sup>1</sup>H  and 77.0 for <sup>13</sup>C NMR). Chemical shifts are also reported downfield from internal SiMe<sub>4</sub> (<sup>1</sup>H) or external CFCl<sub>3</sub> (<sup>19</sup>F). Splitting patterns were reported as following: s: singlet, d: doublet, t: triplet, m: multiplet. <italic>J</italic> values are reported in Hz. Melting points were determined on a Boetius apparatus and were uncorrected. High                  resolution mass spectra (HRMS) were recorded on an   Agilent Q-TOF 6550 Instrument (USA) using ESI (electrospray ionization).</p>
    </sec>
    <sec id="idm1842127148">
      <title>Experimental Procedures</title>
      <sec id="idm1842126788">
        <title>Synthesis of Cladribine 3, 5 and -2-</title>
        <p><italic>Synthesis of 2,6-dichloro-9-(3</italic>′<italic>,5</italic>′<italic>-di-O-p-toluoyl-2</italic>′<italic>-deoxy-β-D-ribofuranosyl)-9H-purine (</italic>2<italic>)</italic></p>
        <p>a<sub>1</sub>) Potassium <italic>t</italic>-butoxide (0.022 g, 0.18 mmol) was added to 2,6-dichloropurine (0.036 g, 0.19 mmol) in anhydrous 1,2-dimethoxyethane (3 ml) at 0 <sup>0</sup>C and then the resulting solution was stirred for 7 min under cooling and then for 15 min at room temperature and evaporated to dryness. Anhydrous acetonitrile (2.5 ml) and                         tetrahydrofuran (2.9 ml) were added to the residue and the suspension was stirred under argon at room                      temperature for 15 min, then the crystalline chloride 1 (0.07 g, 0.18 mmol) was gradually added during 10 min. The reaction mixture was stirred under argon at room temperature for 240 min. Insoluble materials were                  removed by filtration and the solids were washed with MeCN (5 mL). The solvent was removed under reduced pressure and the residue was chromatographed on silica gel, eluting with toluene/acetone 9:1 to afford                                 β-nucleoside <bold>2</bold> as a white solid (0.068 g, 70%). Mp.                  159-162 <sup>0</sup>С (EtOH).<sup>1</sup>H NMR (CDCl<sub>3, </sub>500 MHz): δ 8.29 (s, 1Н, Н-8), 7.97, 7.82, 7.28, 7.20 (4d, 8Н, 2xTol), 6.55 (t, 1Н, <italic>J</italic><sub>1</sub><sub>′,2′</sub>= <italic>J</italic><sub>1</sub><sub>′,2′′</sub> = 6.4 Hz, Н-1′), 5.79 (br.t, 1Н, Н-3′), 4.80 (dd, 1Н, <italic>J</italic><sub>H-5′,H-4′</sub>= 2.7 Hz, <italic>J</italic><sub>H5′,H5′′</sub> = 10.5 Hz, Н-5′), 4.64-4.69 (m, 2Н, Н-4′ и Н-5′′), 2.94-2.97 (m, 2Н, Н-2′ and H-2′′), 2.45 (s, 3Н, CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>CO) and 2.41 (s, 3Н, CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>CO). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 126.76 MHz): δ 166.0 and 165.9 (<italic>СО</italic>C<sub>6</sub>H<sub>4</sub>CH<sub>3</sub>), 153.0, 152.2, 151.9, 144.6, 144.4, 143.7, 131.2, 129.8, 129.5, 129.4, 129.3, 126.3, 126.1 (С-6, С-2, С-4, С-5, С-8, 2xCH<sub>3</sub><italic>C</italic><sub><italic>6</italic></sub><italic>H</italic><sub><italic>4</italic></sub>CO), 85.3 (С-4′), 83.6 (С-1′), 74.9 (С-3′), 63.7 (С-5′), 38.5 (C-2′), 21.7 and 21.6 (2x<italic>CH</italic><sub><italic>3</italic></sub>C<sub>6</sub>H<sub>4</sub>CO). HRMS (ESI) calcd for C<sub>26</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>5</sub> (M + Na)<sup>+</sup>: 563,0865, found 563,0862.</p>
        <p>a<sub>3</sub>) Potassium <italic>t</italic>-butoxide (0.029 g, 0.24 mmol) was added to 2,6-dichloropurine (0.052 g, 0.28 mmol) in anhydrous 1,2-dimethoxyethane (4 ml) at 0 <sup>0</sup>C and then the resulting solution was stirred for 7 min under cooling and then for 15 min at room temperature and evaporated to dryness. Anhydrous acetonitrile (4 ml) and freshly              distilled 3,4-dihydropyrane (4.4 ml) were added to the residue and the suspension was stirred under argon at room temperature for 15 min, then the crystalline chloride 1 (0.1 g, 0.26 mmol) was gradually added during 10 min. The reaction mixture was stirred under argon at room temperature for 210 min. Insoluble materials were                   removed by filtration and the solids were washed with MeCN (20 mL). The solvent was removed under reduced pressure and the residue was chromatographed on silica gel, eluting with EtOAc/petroleum ether 3:1 and 2:1 to afford β-nucleoside <bold>2</bold> a white solid (0.094 g, 67%). </p>
      </sec>
      <sec id="idm1842103676">
        <title>Synthesis of 2-chloro-2′-deoxyadenosine (3)</title>
        <p>To a solution of β-nucleoside 2 (0.3g<italic>, </italic>0.55 mmol)in anhydrous THF (14 mL) was added in 50 ml methanol saturated at 0 <sup>0</sup>C with ammonia, the reaction mixture was stirring for 24 h at room temperature, then for 18 h under 35-40 <sup>0</sup>C and evaporated. The residue was                              chromatographed on silica gel using for elution CHCl<sub>3</sub>,then CHCl<sub>3</sub>:MeOH-15:1 and 5:1 to afford nucleoside <bold>3 </bold>as a white solid(0.13 g, 82%).Mp. &gt;300 <sup>0</sup>С (methanol).<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 500 MHz): δ 8.36 (s, 1Н, Н-8), 7.82 (br. s , 2Н, NH<sub>2</sub>), 6.27 (t, 1Н, <italic>J</italic><sub>1</sub>′<sub>,2</sub>′= <italic>J</italic><sub>1</sub>′<sub>,2</sub>′′ = 6.4 Hz, Н-1′), 5.40 (d, 1Н, <italic>J</italic><sub>3</sub>′<sub>,3-ОН</sub> = 4.2, 2′-ОН), 5.04 (t, 1Н, <italic>J</italic><sub>5</sub>′<sub>,5-ОН</sub> = 5.4, 5′-OH), 4.10 (m, 1Н, Н-3′), 3.87 (m, 1Н, Н-4′). 3.53-3.62 (m, 2Н,             Н-5′ and Н-5′′), 2.61 (ddd, 1Н, Н-2′), 2.32 (ddd, 1Н, Н-2′′). <xref ref-type="bibr" rid="ridm1841919084">13</xref>C NMR (DMSO-d<sub>6</sub>, 126.76 MHz): δ 156.8, 153.3, 150.1, 139.9, 118.2, 87.9, 83.6, 70.7, 61.7, 39.8. HRMS (ESI) calcd for C<sub>10</sub>H<sub>12</sub>ClN<sub>5</sub>O<sub>3</sub>: 286.0707 (M+H), found 286.0701.</p>
      </sec>
      <sec id="idm1842111092">
        <title>Synthesis of Purine Modified Nucleoside Analogues 4, 5, 6 and 14</title>
        <sec id="idm1842109868">
          <title>Synthesis of 2-chloro-6-fluoro-9-(3′,5′-di-O-p-toluoyl-2′-deoxy-β-D-ribofuranosyl)-9H-purine (4). </title>
          <p>To a solution of 3′,5′-di-O-toluoyl-2,6-dichloropurine-2′-deoxyriboside (<bold>2</bold>) (0.06 g, 0.11 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2 </sub>(3.7 ml) and pyridine (0.022 ml) was added dropwise 0.095 ml (0.72 mmоl) DAST at room                 temperature. The reaction mixture was stirred for 30 min at rt and 23 h at 40-45 <sup>0</sup>C, then evaporated. The residue was chromatographed on silica gel using for elution                 mixtures 7:1, 5:1 and 3:1 hexane-EtOAc. Nucleoside 4 (0.034 g, 58%) was prepared as a syrup. Mp. 142-143 <sup>0</sup>С (ethylacetate/hexane).<sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.32 (s, 1H, H-8), 8.02 (d, 2H, Tol), 7.88 (d, 2H, Tol), 7.33 (d, 2H, Tol), 7.25 (d, 2H, Tol), 6.61 (t, 1H,<italic> J</italic>= 5.9 Hz, <italic>J </italic>= 6.9 Hz,                H-1′), 5.82-5.86 (m, 1H, H-3′), 4.83 (dd, 1H,<italic> J</italic><sub>H-5′,H-4′ </sub>= 6.8 Hz, <italic>J</italic><sub>H5′,H5′′</sub> = 11.0 Hz, H-5′), 4.67-4.75 (m, 2H, H-4′ and                  H-5′′), 2.98-3.05 (m, 2H,H-2′ and H-2′′), 2.49 (s, 3H, Tol), 2.45 (s, 3H, Tol). <sup>13</sup>C NMR (CDCl<sub>3</sub>,126.76 MHz): δ 166.1 and 166.0 (C=O, Tol), 159.3 (d, <italic>J </italic>= 265.0 Hz), 155.9                    (d, <italic>J</italic> = 11.2 Hz), 152.7 (d, <italic>J </italic>= 16.6 Hz), 144.8, 144.5, 143.5 (d, <italic>J</italic><sub>C-8,F-6 </sub>~ 2.0 Hz, C-8), 129.9, 129.6,129.4, 126.4, 126.2, 119.7, 85.4 (C-4′), 83.7 (C-1′), 74.9 (C-3′), 63.8 (C-5′), 38.6 (C-2′), 21.8 (<italic>CH</italic><sub><italic>3</italic></sub>C<sub>6</sub>H<sub>5</sub>CO-), 21.7 (<italic>CH</italic><sub><italic>3</italic></sub>C<sub>6</sub>H<sub>5</sub>CO-). <sup>19</sup>F NMR (CDCl<sub>3, </sub>470.59 MHz): δ -65.59 (s, F-6). HRMS (ESI) calcd for C<sub>26</sub>H<sub>22</sub>ClFN<sub>4</sub>O<sub>5</sub><sup>M+Na</sup><sup>+</sup>: 547.1160, found 547.1157.</p>
        </sec>
        <sec id="idm1842080364">
          <title>Synthesis of 2-chloro-6-isopropylamino-9-(3′,5′-di-O-p-toluoyl-2′-deoxy-β-D-ribofuranosyl)-9H-purine (5)</title>
          <p>To a solution of 3′,5′-di-O-toluoyl-2-chloro-6-fluoropurine-2′-deoxyriboside (4) (0.018 g, 0.0034 mmol) in anhydrous 1,2-DME(2.0 ml) was added 0.013 ml (0.17 mmоl) isopropyl amine at room temperature. The reaction mixture was stirred for 70 min and then evaporated. The residue was chromatographed on a silica gel, using a               mixture of 4:1, 2:1, 1:1 and hexane-EtOAc to affordnucleoside 5(0.017 g, 89%)as a syrup. Mp.72-74 <sup>0</sup>С (MeOH).<sup>1</sup>H NMR (CDCl<sub>3, </sub>500 MHz): δ 8.02 (d, 2H, Tol), 7.97 (s, 1H, H-8), 7.93 (d, 2H, Tol), 7.33 (d, 2H, Tol), 7.27 (d, 2H, Tol), 6.56 (t, 1H,<italic> J</italic><sub>1′,2′</sub>= <italic>J</italic><sub>1′,2′′</sub> = 6.4 Hz, H-1′), 6.02 (br. s, 1H, NH), 5.75-5.83 (m, 1H, H-3′), 4.78 (dd, 1H,                     <italic>J</italic><sub>H-5′,H-4′  </sub>= 3.2 Hz, <italic>J</italic><sub>H5′,H5′′</sub> = 11.0 Hz, H-5′), 4.69 (dd, 1H,                <italic>J</italic><sub>H-5′′,H-4′  </sub>= 3.3 Hz, H-5′′), 4.63-4.70 (m, 1H, H-4′), 4.52 [br. s, 1H, HN<italic>CH</italic>(CH<sub>3</sub>)<sub>2</sub>], 2.90-2.93 (m, 2H,H-2′ and H-2′′), 2.49 (s, 3H, Tol), 2.45 (s, 3H, Tol), 1.35 [d, 3H, <italic>J</italic> = 0.9 Hz, CH(<italic>CH</italic><sub><italic>3</italic></sub>)<sub>2</sub>], 1.34 [d, 3H,<italic> J</italic> = 0.9 Hz, CH(<italic>CH</italic><sub><italic>3</italic></sub>)<sub>2</sub>]. <sup>13</sup>C NMR (CDCl<sub>3</sub>,126.76 MHz): δ 166.2 and 166.0 (C=O, Tol), 154.5, 144.6, 144.3, 137.4, 129.9, 129.6,129.4, 129.3, 126.7, 126.4 (C-6, C-2, C-4, C-8, C-5, CH<sub>3</sub><italic>C</italic><sub><italic>6</italic></sub><italic>H</italic><sub><italic>5</italic></sub>CO-), 84.6 (C-4′), 83.2 (C-1′), 75.1 (C-3′), 64.1 (C-5′), 42.8 [<italic>CH</italic>(CH<sub>3</sub>)<sub>2</sub>], 38.7 (C-2′), 22.8 [CH(<italic>CH</italic><sub><italic>3</italic></sub>)<sub>2</sub>], 21.8 (<italic>CH</italic><sub><italic>3</italic></sub>C<sub>6</sub>H<sub>5</sub>CO), 21.7 (<italic>CH</italic><sub><italic>3</italic></sub>C<sub>6</sub>H<sub>5</sub>CO).HRMS (ESI): m/z calcd for C<sub>29</sub>H<sub>30</sub>N<sub>5</sub>O<sub>5</sub>Cl (M+Na)<sup>+</sup>: 586.1883, found 586.1878.</p>
        </sec>
        <sec id="idm1842060044">
          <title>Synthesis of 2-chloro-6-isopropylamino-9-(2′-deoxy-β-D-ribofuranosyl)-9H-purine (6)</title>
          <p>A solution of nucleoside 5 (0.034 g, 0.06 mmol)in MeOH (4 mL) saturated at 0 <sup>0</sup>C with ammonia was kept for 18 h at room temperature and then evaporated. The                  residue was chromatographed on silica gel, eluting with CHCl<sub>3</sub>,then CHCl<sub>3</sub>:MeOH-20:1, 15:1 and 8:1 to afford                 nucleoside 6 (15.6 mg, 79%). Mp.124-126 <sup>0</sup>С (MeOH).<sup>1</sup>H NMR (CD<sub>3</sub>OD, 500 MHz): δ 8.25 (s, 1H, H-8), 6.39 (dd, 1H, <italic>J</italic><sub>1′,2′ </sub>= <italic>J</italic><sub>1′, 2′′ </sub>= 6.2 Hz, H-1′), 4.58-4.61 (m, 1H, H-3′), 4.43 [br. s, 1H, HN<italic>CH</italic>(CH<sub>3</sub>)<sub>2</sub>], 4.07 (q, 1H, H-4′), 3.87 (dd, 1H,               <italic>J</italic><sub>5′,4′ </sub>= 3.2 Hz, <italic>J</italic><sub>5′,5′′ </sub>= 12.2 Hz, H-5′), 3.76 (dd, 1H, <italic>J</italic><sub>5′′,4′ </sub>= 3.6 Hz, H-5′′), 2.87 (ddd, 1H, <italic>J </italic>= 5.5 Hz,<italic> J </italic>= 6.2 Hz, <italic>J </italic>= 12.3 Hz, H-2′), 2.42 (ddd, 1H, <italic>J </italic>= 2.7 Hz,<italic> J </italic>= 6.2 Hz, H-2′′), 1.33 [br.s, 1H, CH(<italic>CH</italic><sub><italic>3</italic></sub>)<sub>2</sub>], 1.31 [br.s, 1H, CH(<italic>CH</italic><sub><italic>3</italic></sub>)<sub>2</sub>]. <sup>13</sup>C NMR (CD<sub>3</sub>OD, 126.76 MHz): δ 155.9, 155.6, 150.6, 120.1, 89.8, 87.0, 72.9, 74.8, 63.6, 43.8, 41.5, 22.7. HRMS (ESI): m/z calcd for C<sub>13</sub>H<sub>18</sub>N<sub>5</sub>O<sub>3</sub>Cl <sup>M+Na</sup><sup>+</sup>: 350.0996, found 350.0983. </p>
        </sec>
        <sec id="idm1842067316">
          <title>Synthesis of 2-chloro-4,5-dihydroxy-3′,5′-di-O-p-toluoyl-2′-deoxyinosine (14). </title>
          <p>To a solution of 3′,5′-di-O-toluoyl-2,6-dichloropurine-2′-deoxyriboside (<bold>2</bold>) (0.06 g, 0.11 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2 </sub>(3.7 ml) and pyridine (0.022 ml) was added dropwise 0.095 ml (0.72 mmоl) DAST at room             temperature. The reaction mixture was stirred for 30 min and 23 h at 40-45 <sup>0</sup>C, then evaporated. To the residue was added 4.0 ml aq. NaHCO<sub>3</sub> and acetonitrile (1.2 ml) and    reaction mixture was stirred at rt for 24 h. then water phase was extracted with CHCl<sub>3</sub>(3x20ml), combined             organic layer was washed with water and dried over              sodium sulfate. The residue was chromatographed on   silica gel, using for elution mixtures of 6:1, 5:1 and 3:1   petrolium ether-EtOAc to afford nucleoside 14 (0.023 g, 65%) as oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.03 (s, 1H, H-8), 8.02 (d, 2H, Tol), 7.88 (d, 2H, Tol), 7.33 (d, 2H, Tol), 7.26 (d, 2H, Tol), 6.59 (t, 1H, <italic>J</italic><sub>1</sub>′<sub>,2</sub>′= <italic>J</italic><sub>1</sub>′<sub>,2</sub>′′ = 6.4 Hz, H-1′),                   5.77-5.80 (m, 1H, H-3′), 4.75 (dd, 1H, <italic>J</italic><sub>H-5′,H-4′  </sub>= 3.3 Hz, <italic>J</italic><sub>H5′,H5′′</sub> = 11.0 Hz, H-5′), 4.71 (dd, 1H, <italic>J</italic><sub>H-5′′,H-4′ </sub>= 4.1 Hz,                       H-5′′), 5.65-5.67 (m, 1H, H-4′), 4.2 (br.s, 1.6H, OH), 3.9 (br.s, 1.4H, OH), 2.91-2.93 (m, 2H,H-2′ and H-2′′), 2.49 (s, 3H, Tol), 2.45 (s, 3H, Tol). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 126.76 MHz): δ 166.2 and 166.0 (C=O, Tol), 154.3, 153.8, 151.1, 144.5, 144.2, 136.2 129.9, 129.7,129.3, 126.7, 126.4, 118.2, 84.5 (C-4′), 83.1 (C-1′), 75.1 (C-3′), 64.2 (C-5′), 38.6 (C-2′), 21.8 (<italic>CH</italic><sub><italic>3</italic></sub>C<sub>6</sub>H<sub>5</sub>CO-), 21.7 (<italic>CH</italic><sub><italic>3</italic></sub>C<sub>6</sub>H<sub>5</sub>CO-). LS (ESI) calcd for C<sub>26</sub>H<sub>25</sub>ClN<sub>4</sub>O<sub>8</sub><sup>M+Na</sup><sup>+</sup>: 578.7, found 578.7.</p>
        </sec>
      </sec>
    </sec>
    <sec id="idm1842036300">
      <title>Acknowledgments </title>
      <p>This study was supported by grant from FOI «Chemical processes, reagents and technologies, bioregulators and bioorgchemistry», s/p «Chemical            foundations of life activity processes» (Bioorgchemisrty 2.3.2.2). </p>
      <p>
        <ext-link xlink:href="Supporting%20Information.docx" ext-link-type="uri">Supplementary Information</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="ridm1842115644">
        <label>1.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Inwards</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Fishkin</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Laplant</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Drake</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kurtin</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Phase I trial of rituximab, cladribine and temsirolimus (RCT) for initial therapy of mantle cell lymphoma</article-title>
          <date>
            <year>2014</year>
          </date>
          <source>Ann.Oncol</source>
          <volume>25</volume>
          <issue>10</issue>
          <fpage>2020</fpage>
          <lpage>2024</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1842184332">
        <label>2.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Shelton</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Hollenbaugh</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cho</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Amblard</surname>
            <given-names>F</given-names>
          </name>
          <article-title>Metabolism biochemical actions, and chemical synthesis of anticancer nucleosides, nucleotides, and base analogs</article-title>
          <date>
            <year>2016</year>
          </date>
          <source>Chem. Rev</source>
          <volume>116</volume>
          <issue>23</issue>
          <fpage>14379</fpage>
          <lpage>14455</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1842193044">
        <label>3.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Robak</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Korycka</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lech-Maranda</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Robak</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases</article-title>
          <date>
            <year>2009</year>
          </date>
          <source>Molecules</source>
          <volume>14</volume>
          <fpage>1183</fpage>
          <lpage>1226</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841972924">
        <label>4.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Schreiber</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Sorensen</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Cladribine treatment of multiple sclerosis</article-title>
          <date>
            <year>2011</year>
          </date>
          <source>Medicine. Clin. Invest</source>
          <volume>1</volume>
          <issue>2</issue>
          <fpage>317</fpage>
          <lpage>326</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841969684">
        <label>5.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Mulakayata</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Rao</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Iqbat</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Bandichhor</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Oruganti</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Synthesis of novel theraupetic agents for the treatment of multiple sclerosis. A brief overreview</article-title>
          <date>
            <year>2013</year>
          </date>
          <source>Eur. J. Med. Chem</source>
          <volume>80</volume>
          <fpage>170</fpage>
          <lpage>186</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841957276">
        <label>6.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Henschke</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Mei</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Chu</surname>
            <given-names>G</given-names>
          </name>
          <article-title>A stereoselective process for the manufature of a 2′-deoxy-β-D-ribonucleoside using the Vorbruggen glycosylation</article-title>
          <date>
            <year>2013</year>
          </date>
          <source>Org. Process Res.&amp; Dev</source>
          <volume>17</volume>
          <fpage>1419</fpage>
          <lpage>1429</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841961668">
        <label>7.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Kazimierczuk</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Cottam</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Revamkar</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Robins</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Synthesis 2-deoxyrtubercidin, 2′-deoxyadenosine and related 2′-deoxynucleosides via a novel direct sterospecific sodium salt glycosylation procedure</article-title>
          <date>
            <year>1984</year>
          </date>
          <source>J.Am.Chem.Soc</source>
          <volume>106</volume>
          <issue>21</issue>
          <fpage>6379</fpage>
          <lpage>6382</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841950500">
        <label>8.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Hildebrand</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wright</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Sodium salt glycosylation in the synthesis of purine 2-deoxyribonucleosides: studies of isomer distribution</article-title>
          <date>
            <year>1992</year>
          </date>
          <source>J.Org.Chem</source>
          <volume>57</volume>
          <issue>6</issue>
          <fpage>1808</fpage>
          <lpage>1813</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841946612">
        <label>9.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Yang</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>B</given-names>
          </name>
          <article-title>A dramatic concentration effect on the stereoselectiveity of N-glycosylation for the synthesis of 2′-deoxy-β-ribonucleosides</article-title>
          <date>
            <year>2012</year>
          </date>
          <source>Chem.Commun</source>
          <volume>48</volume>
          <fpage>7097</fpage>
          <lpage>7099</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841930676">
        <label>10.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Xia</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>L</given-names>
          </name>
          <article-title>Efficient synthesis of cladribine via the metal-free deoxygenation</article-title>
          <date>
            <year>2015</year>
          </date>
          <source>Nucleosides, Nucleotides Nucleic Acids</source>
          <volume>34</volume>
          <fpage>729</fpage>
          <lpage>735</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841925924">
        <label>11.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Mikhailopulo</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Zinchenko</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kazimierczuk</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Barai</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Bokut</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Synthesis of 2-chloro 2′-deoxyadenosine by microbiological trans glycosylation</article-title>
          <date>
            <year>1993</year>
          </date>
          <fpage>417</fpage>
          <lpage>422</lpage>
          <publisher-loc>Nucleosides, Nucleotides12(3-4):</publisher-loc>
        </mixed-citation>
      </ref>
      <ref id="ridm1841921676">
        <label>12.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Komatsu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Araki</surname>
            <given-names>T</given-names>
          </name>
          <article-title>Efficient chemo-enzymatic syntheses of pharmaceutically useful unnatural 2′-deoxynucleosides, Nucleosides, Nucleotides Nucleic Acids24(5-7):</article-title>
          <date>
            <year>2005</year>
          </date>
          <fpage>1127</fpage>
          <lpage>1130</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841919084">
        <label>13.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Artemyeva</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Remeeeva</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Buravskaya</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Konstantinova</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Esipov</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Anion exchange resins in phosphate form as versatile carriers for the reactions catalyzed by nucleoside phosphorylases</article-title>
          <date>
            <year>2020</year>
          </date>
          <source>Beilstein J. Org. Chem</source>
          <volume>26</volume>
          <fpage>2607</fpage>
          <lpage>2622</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841901420">
        <label>14.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Znong</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Novak</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Robins</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Regiospesific and highly streoselective coupling of 6-(substituted-imidazol-1-yl)purines with 2-deoxy-3,5-di-O-(p-toluoyl)-D-erythro-pentofuranosyl chloride. Sodium-salt glycosylation in binary solvent mixtures: improved synthesis of cladribine</article-title>
          <date>
            <year>2006</year>
          </date>
          <source>J. Org. Chem</source>
          <volume>71</volume>
          <issue>20</issue>
          <fpage>7773</fpage>
          <lpage>7779</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841895372">
        <label>15.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Satishkumar</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Vuram</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Relangi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Gurram</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Cladribine analogues via O6-(benzotriazolyl) derivatives of guanine nucleosides</article-title>
          <date>
            <year>2015</year>
          </date>
          <source>Molecules</source>
          <volume>20</volume>
          <fpage>181</fpage>
          <lpage>202</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841908764">
        <label>16.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Salvatori</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Volpini</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Vincenzetti</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Vita</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Costanzi</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Adenine and deazaadenine nucleoside and deoxynucleoside analogues: inhibition of viral replication of sheep MVV (in vitro model for HIV) and bovine BHV-1</article-title>
          <date>
            <year>2002</year>
          </date>
          <source>Bioorg. Med. Chem</source>
          <volume>10</volume>
          <fpage>2973</fpage>
          <lpage>2980</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841902428">
        <label>17.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Rolland</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Kotera</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lhomme</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Convenient preparation of 2-deoxy-3,5-di-O-p-toluoyl-α-D-erythro-pentofuranosyl chloride</article-title>
          <date>
            <year>1997</year>
          </date>
          <source>Synth. Commun</source>
          <volume>27</volume>
          <issue>2</issue>
          <fpage>3505</fpage>
          <lpage>3511</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841873748">
        <label>18.</label>
        <mixed-citation xlink:type="simple" publication-type="book">
          <name>
            <surname>Drenichev</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Oslovsky</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Mikhailov</surname>
            <given-names>S</given-names>
          </name>
          <date>
            <year>2016</year>
          </date>
          <chapter-title>Cytokinin Nucleosides – Natural Compounds with a Unique Spectrum of Biological Activities, Current Topics in Med. Chem.16</chapter-title>
          <fpage>2562</fpage>
          <lpage>2576</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841872740">
        <label>19.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Robins</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Yznanski</surname>
            <given-names>B</given-names>
          </name>
          <article-title>Nucleic acid related compounds. 34. Non-aqueous diazotization with tert-butyl nitrite. Introduction of fluorine, chlorine, and bromine at C-2 purine nucleosides</article-title>
          <date>
            <year>1981</year>
          </date>
          <source>Can J. Chem</source>
          <volume>59</volume>
          <fpage>2608</fpage>
          <lpage>2611</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841867772">
        <label>20.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Liu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Robins</surname>
            <given-names>M</given-names>
          </name>
          <article-title>SNAr Displacements with 6-(Fluoro</article-title>
          <date>
            <year>2007</year>
          </date>
          <source>Chloro, Bromo, Iodo, and Alkylsulfonyl)purine Nucleosides: Synthesis, Kinetics, and Mechanism, J. Am. Chem. Soc</source>
          <volume>129</volume>
          <issue>16</issue>
          <fpage>5962</fpage>
          <lpage>5968</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841862516">
        <label>21.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Deng</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Xiang</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>L</given-names>
          </name>
          <article-title>The new convenient synthesis of 6-fluoropurine and its 7-/9-unsubstituted analogues</article-title>
          <date>
            <year>2012</year>
          </date>
          <source>Heterocycles</source>
          <volume>85</volume>
          <issue>12</issue>
          <fpage>2999</fpage>
          <lpage>3006</lpage>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
